CG

Cullinan Oncology IncNASDAQ CGEM Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

1.238

Small

Exchange

XNAS - Nasdaq

CGEM Stock Analysis

CG

Uncovered

Cullinan Oncology Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

1.238

Dividend yield

Shares outstanding

39.327 B

Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

View Section: Eyestock Rating